← Leaderboards
Bruce J Dezube
Beth Israel Deaconess Medical Center
$965,277
Attributed
$965,277
Total exposure
10
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $204.9K · FY2005–07$250K$187.5K$125K$62.5K$0
'05
'06
'07
Funding mix
By agency
NIH$965,277 · 10
By mechanism
M01$815,277 · 9
U01$150,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Mary Albrecht$387,832
- Jerome E Groopman$14,405,534
- Marshall R Posner$5,601,889
- Scott Hammer$387,832
- Henry B Koon$1,202,793
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectDrug Screening /EvaluationClinical Trial Phase IHuman Therapy EvaluationHiv InfectionsDrug Adverse EffectPharmacokineticsAids TherapyDosageIntravenous AdministrationKaposi'S SarcomaDrug InteractionsAntiaids AgentProtease InhibitorVirus ReplicationAntiidiotype AntibodyAngiogenesisIndinavirLamivudineFibroblast Growth FactorCd4 MoleculeCytotoxic T LymphocyteAntineoplastics
Grant awards (29)
NOVEL IMMUNOMODULATOR A-007 OF HUMAN PAPPILOMAVIRUS INFECTION: A PHASE II STUDY$1,174
M01 · FY2007 · RR · contact PI
Beth Israel Deaconess Medical Center$150,000
U01 · FY2006 · CA · contact PI
NOVEL IMMUNOMODULATOR A-007 OF HUMAN PAPILLOMAVIRUS INFECTION: A PHASE II STUDY$502
M01 · FY2006 · RR · contact PI
PHASE I TRIAL OF PEHRG214 IN PATIENTS WITH HIV INFECTION$204,463
M01 · FY2005 · RR
ORAL BIOLOGY OF THE KS-ASSOCIATED HERPES VIRUS$455
M01 · FY2005 · RR
Phase I trial of PEHRG214 in Patients with HIV infection$215,674
M01 · FY2004 · RR
ORAL BIOLOGY OF THE KS-ASSOCIATED HERPES VIRUS$5,177
M01 · FY2004 · RR
POTENTIAL INTERACTIONS BETWEEN PACLITAXEL &PROTEASE INHIBITORS IN KS$0
M01 · FY2002 · RR
PHASE I TRIAL OF COL 3 IN HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2002 · RR
TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION$0
M01 · FY2002 · RR
INTERACTION BETWEEN S 1153 &NELFINAVIR &INDINAVIR IN HIV$0
M01 · FY2002 · RR
INTERACTION BETWEEN S 1153 &NELFINAVIR &INDINAVIR IN HIV$0
M01 · FY2001 · RR
POTENTIAL INTERACTIONS BETWEEN PACLITAXEL &PROTEASE INHIBITORS IN KS$0
M01 · FY2001 · RR
TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION$0
M01 · FY2001 · RR
PHASE I TRIAL OF COL 3 IN HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2001 · RR
PHASE I TRIAL OF S-1153 IN PATIENTS WITH HIV INFECTION$193,916
M01 · FY2000 · RR
PHASE I TRIAL OF S-1153 IN PATIENTS WITH HIV INFECTION$193,916
M01 · FY2000 · RR
PHASE I TRIAL OF COL 3 IN HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR
TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION$0
M01 · FY2000 · RR
TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION$0
M01 · FY2000 · RR
TRIAL OF HNM01 IN PATIENTS WITH HIV INFECTION$0
M01 · FY2000 · RR
INTERACTION BETWEEN S 1153 &NELFINAVIR &INDINAVIR IN HIV$0
M01 · FY2000 · RR
POTENTIAL INTERACTIONS BETWEEN PACLITAXEL &PROTEASE INHIBITORS IN KS$0
M01 · FY2000 · RR
POTENTIAL INTERACTIONS BETWEEN PACLITAXEL &PROTEASE INHIBITORS IN KS$0
M01 · FY2000 · RR
INTERACTION BETWEEN S 1153 &NELFINAVIR &INDINAVIR IN HIV$0
M01 · FY2000 · RR
PHASE I TRIAL OF COL 3 IN HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR
PHASE I TRIAL OF COL 3 IN HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR
POTENTIAL INTERACTIONS BETWEEN PACLITAXEL &PROTEASE INHIBITORS IN KS$0
M01 · FY2000 · RR
INTERACTION BETWEEN S 1153 &NELFINAVIR &INDINAVIR IN HIV$0
M01 · FY2000 · RR